Sean O’Connor Named President and CEO of Nucelis

  Sean O’Connor Named President and CEO of Nucelis

Business Wire

NEW YORK -- March 4, 2013

The Board of Directors of Nucelis Corporation announced that it has named Dr.
Sean P. O’Connor as president and CEO, effective immediately. In his new role,
Dr. O’Connor will tap his significant experience in the specialty chemical
industry and will also serve as a member of the board of directors.

Dr. O’Connor has served in a number of senior business management roles at
Chemtura Corporation, most recently as President of Chemtura’s Petroleum
Additives business unit based in Connecticut. He previously managed Chemtura’s
Polymer Additives portfolio, which generated revenues of over $1B from
manufacturing and marketing additives used in PVC, polyolefins and in
engineering plastics. Prior to this, he worked in a number of different roles
at British Petroleum in the United Kingdom. He has a PhD in organic chemistry
from the University of Bristol.

“On behalf of the board, I am delighted to welcome Sean to Nucelis so he can
build the company to reach its significant potential,” said Rory Riggs,
chairman. “Dr. O’Connor has a great blend of commercial and technology
experience including a long history of successfully commercializing new
products.”

“Nucelis has developed a highly differentiated technology, and I am very
excited to be given the opportunity to realize value from this for the
shareholders and our customers,” Dr. O’Connor said. “I look forward to working
with the board and the outstanding employees already in place in Nucelis to
build this enterprise into a biotechnology powerhouse.”

Nucelis Corporation  is a pioneering specialty chemicals company with a
unique, patented technology for modifying cell structure and function. The
technology has broad and potentially significant commercial value in numerous
industries that are now turning to sustainable and renewable products and
chemistry. These include the cosmetics industry, products for the food and
fragrance industries, and specialty edible oils with particular health
benefits. The company has recently initiated product development programs in
yeast and certain crop plants to address some of these opportunities. In some
cases, Nucelis applications hold the promise to offer an alternative source to
products currently sourced from endangered species.

Nucelis uses its unique patented technology, Rapid Trait Development System
(“RTDS™”), which relies on the cell’s own repair mechanism to implement
changes, rather than inserting foreign materials into a cell’s DNA sequence.
RTDS has been certified as non-transgenic by the US Department of Agriculture.
The categorization of the technology as distinct from transgenic, or
Genetically Modified (“GM”), methods gives Nucelis a protected competitive
position in major agricultural-producer locations, such as Europe, where GM is
not well accepted. It also allows for much shorter and less costly
development/certification processes in those geographies where Nucelis
products would be competing with transgenic products such as in the United
States.

For more information, please visit www.nucelis.com.

Contact:

For Nucelis Corporation:
Shawna Seldon, 917-971-7852
shawna@rosengrouppr.com